Pre-treatment Serum Albumin and Mutational Burden As Biomarkers of Response to Immune Checkpoint Blockade

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2022 Apr 8

PMID 35393553

Authors

Seong-Keun Yoo

Diego Chowell

Cristina Valero

Luc G T Morris

Timothy A Chan

Affiliations

Soon will be listed here.

Abstract

The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

Citing Articles

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.

Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L J Immunother Cancer. 2025; 13(3).

PMID: 40054999 PMC: 11891540. DOI: 10.1136/jitc-2024-010928.

Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers.

Arango-Argoty G, Kipkogei E, Stewart R, Sun G, Patra A, Kagiampakis I Nat Commun. 2025; 16(1):2101.

PMID: 40025003 PMC: 11873189. DOI: 10.1038/s41467-025-57181-2.

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.

Yoo S, Fitzgerald C, Cho B, Fitzgerald B, Han C, Koh E Nat Med. 2025; .

PMID: 39762425 DOI: 10.1038/s41591-024-03398-5.

Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.

Cowzer D, Chou J, Walch H, Keane F, Khalil D, Shia J Oncologist. 2024; 29(10):894-903.

PMID: 38937977 PMC: 11448888. DOI: 10.1093/oncolo/oyae110.

Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer.

Kuang Z, Miao J, Zhang X Front Immunol. 2024; 15:1327449.

PMID: 38911864 PMC: 11190784. DOI: 10.3389/fimmu.2024.1327449.

References

Valero C, Zanoni D, McGill M, Ganly I, Morris L, Quer M . Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. Cancer. 2019; 126(5):994-1003. PMC: 7971350. DOI: 10.1002/cncr.32591. View

Tang S, Leung J, Abe K, Chan K, Chan L, Chan T . Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003; 111(4):515-27. PMC: 151921. DOI: 10.1172/JCI16079. View

Imtiaz F, Shafique K, Mirza S, Ayoob Z, Vart P, Rao S . Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012; 5(1):2. PMC: 3277482. DOI: 10.1186/1755-7682-5-2. View

Hu M, Xu Q, Yang S, Han S, Zhu Y, Lin Q . Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Ann Transl Med. 2020; 8(20):1310. PMC: 7661896. DOI: 10.21037/atm-20-6484. View

Bharadwaj S, Ginoya S, Tandon P, Gohel T, Guirguis J, Vallabh H . Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf). 2016; 4(4):272-280. PMC: 5193064. DOI: 10.1093/gastro/gow013. View

Davoli T, Uno H, Wooten E, Elledge S . Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017; 355(6322). PMC: 5592794. DOI: 10.1126/science.aaf8399. View

Don B, Kaysen G . Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2005; 17(6):432-7. DOI: 10.1111/j.0894-0959.2004.17603.x. View

Soyano A, Dholaria B, Marin-Acevedo J, Diehl N, Hodge D, Luo Y . Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018; 6(1):129. PMC: 6251165. DOI: 10.1186/s40425-018-0447-2. View

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

10.

Wang Z, Aguilar E, Luna J, Dunai C, Khuat L, Le C . Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2018; 25(1):141-151. PMC: 6324991. DOI: 10.1038/s41591-018-0221-5. View

11.

Gupta D, Lis C . Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010; 9:69. PMC: 3019132. DOI: 10.1186/1475-2891-9-69. View

12.

Valero C, Lee M, Hoen D, Weiss K, Kelly D, Adusumilli P . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021; 12(1):729. PMC: 7851155. DOI: 10.1038/s41467-021-20935-9. View

13.

Cheng D, Mitchell T, Zehir A, Shah R, Benayed R, Syed A . Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015; 17(3):251-64. PMC: 5808190. DOI: 10.1016/j.jmoldx.2014.12.006. View

14.

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

17.

Subbiah V, Solit D, Chan T, Kurzrock R . The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020; 31(9):1115-1118. DOI: 10.1016/j.annonc.2020.07.002. View

18.

Yuen K, Liu L, Gupta V, Madireddi S, Keerthivasan S, Li C . High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020; 26(5):693-698. PMC: 8286544. DOI: 10.1038/s41591-020-0860-1. View

19.

Chowell D, Krishna C, Pierini F, Makarov V, Rizvi N, Kuo F . Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019; 25(11):1715-1720. PMC: 7938381. DOI: 10.1038/s41591-019-0639-4. View

20.

Laino A, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M . Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020; 8(1). PMC: 7312339. DOI: 10.1136/jitc-2020-000842. View